The current state of oligometastatic and oligoprogressive non-small cell lung cancer

Vasu Tumati, Puneeth Iyengar

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60% of patients with nonsmall cell lung cancer (NSCLC) present with metastatic disease and another 45% of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.

Original languageEnglish (US)
Pages (from-to)S2537-S2544
JournalJournal of Thoracic Disease
Volume10
DOIs
StatePublished - Aug 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Patient Selection
Neoplasm Metastasis
Therapeutics
Neoplasms

Keywords

  • Metastasectomy
  • Non-small cell lung cancer (NSCLC)
  • Oligometastases
  • Oligoprogressive
  • Stereotactic ablative radiotherapy (SABR)
  • Stereotactic body radiation therapy (SBRT)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The current state of oligometastatic and oligoprogressive non-small cell lung cancer. / Tumati, Vasu; Iyengar, Puneeth.

In: Journal of Thoracic Disease, Vol. 10, 01.08.2018, p. S2537-S2544.

Research output: Contribution to journalReview article

@article{ebdb9aa8eb744baf97e2345c99ad7cd6,
title = "The current state of oligometastatic and oligoprogressive non-small cell lung cancer",
abstract = "Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60{\%} of patients with nonsmall cell lung cancer (NSCLC) present with metastatic disease and another 45{\%} of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.",
keywords = "Metastasectomy, Non-small cell lung cancer (NSCLC), Oligometastases, Oligoprogressive, Stereotactic ablative radiotherapy (SABR), Stereotactic body radiation therapy (SBRT)",
author = "Vasu Tumati and Puneeth Iyengar",
year = "2018",
month = "8",
day = "1",
doi = "10.21037/jtd.2018.07.19",
language = "English (US)",
volume = "10",
pages = "S2537--S2544",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - The current state of oligometastatic and oligoprogressive non-small cell lung cancer

AU - Tumati, Vasu

AU - Iyengar, Puneeth

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60% of patients with nonsmall cell lung cancer (NSCLC) present with metastatic disease and another 45% of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.

AB - Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60% of patients with nonsmall cell lung cancer (NSCLC) present with metastatic disease and another 45% of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.

KW - Metastasectomy

KW - Non-small cell lung cancer (NSCLC)

KW - Oligometastases

KW - Oligoprogressive

KW - Stereotactic ablative radiotherapy (SABR)

KW - Stereotactic body radiation therapy (SBRT)

UR - http://www.scopus.com/inward/record.url?scp=85051259633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051259633&partnerID=8YFLogxK

U2 - 10.21037/jtd.2018.07.19

DO - 10.21037/jtd.2018.07.19

M3 - Review article

C2 - 30206497

AN - SCOPUS:85051259633

VL - 10

SP - S2537-S2544

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

ER -